CEOs Head to JPMorgan Pharma Event With M&A Hopes, High Security
- Focus at JPM event will be on incoming Trump administration
- Security has been tightened after killing of UnitedHealth exec
The stakes for the biotech industry are high, with a swathe of blockbuster drugs facing the end of their exclusivity period.
Photographer: TEK IMAGE/Science Photo Library/Getty Images
This article is for subscribers only.
At the health-care industry’s annual confab this week in San Francisco, talk is likely to be more focused on what’s going on 3,000 miles away — at Mar-a-Lago.
There, at his Florida club, President-elect Donald Trump is preparing for a second White House term that industry executives expect will usher in a new era. They’re hoping for a break from the Biden Administration’s tough antitrust enforcement, and that a laxer regime will embolden pharma companies to pursue splashier deals.